Market capitalization | $4.30b |
Enterprise Value | $4.18b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 14.34 |
P/S ratio (TTM) P/S ratio | 14.76 |
P/B ratio (TTM) P/B ratio | 41.66 |
Revenue growth (TTM) Revenue growth | 59.73% |
Revenue (TTM) Revenue | $291.49m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
17 Analysts have issued a Axsome Therapeutics, Inc. forecast:
17 Analysts have issued a Axsome Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 291 291 |
60%
60%
|
|
Gross Profit | 256 256 |
62%
62%
|
|
EBITDA | -254 -254 |
64%
64%
|
EBIT (Operating Income) EBIT | -262 -262 |
60%
60%
|
Net Profit | -309 -309 |
67%
67%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Head office | United States |
CEO | Herriott Tabuteau |
Employees | 545 |
Founded | 2012 |
Website | www.axsome.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.